Cambium Bio (ASX:CMB) ROCE %: -115.07% (As of Dec. 2025)


ASX:CMB Cambium Bio Ltd ASX:CMB
34 GF Score
Price A$0.42
! 4 Warning Signs
View Full Analysis

What is Cambium Bio ROCE %?

Cambium Bio ASX:CMB -6.74% 34 ROCE % is -115.07% as of Dec. 2025. GuruFocus rates ASX:CMB with a GF Score™ of 34/100. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cambium Bio's annualized ROCE % for the quarter that ended in Dec. 2025 was -115.07%.

Cambium Bio  (ASX:CMB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cambium Bio ROCE % Related Terms

Cambium Bio ROCE % Historical Data

* Premium members only.

The historical data trend for Cambium Bio's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cambium Bio ROCE % Chart

Cambium Bio Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 114.43 -168.10 0.00 -307.04 -145.24

Cambium Bio Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -197.58 -124.54 -205.06 -115.07
ASX:CMB
34GF Score
Cambium Bio Ltd ASX:CMB
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cambium Bio ROCE % Calculation

Cambium Bio's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-3.809/( ( (5.649 - 2.405) + (3.295 - 1.294) )/ 2 )
=-3.809/( (3.244+2.001)/ 2 )
=-3.809/2.6225
=-145.24 %

Cambium Bio's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-2.878/( ( (3.295 - 1.294) + (3.485 - 0.484) )/ 2 )
=-2.878/( ( 2.001 + 3.001 )/ 2 )
=-2.878/2.501
=-115.07 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -115.07% mean?
Cambium Bio (ASX:CMB) has a ROCE % of -115.07% as of Dec. 2025.
Is Cambium Bio's ROCE % too high?
Cambium Bio's current ROCE % is -115.07%. Overall, Cambium Bio has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's ROCE % compare to VRTX and REGN?
Cambium Bio's ROCE % of -115.07% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Cambium Bio's current ROCE % is -115.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current ROCE % of -115.07%. The current ROCE % is -115.07%. Cambium Bio's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current ROCE % is -115.07% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambium Bio Business Description

Address Unit 2.06, 31 Lexington Drive, Bella Vista, NSW, AUS, 2153
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
34GF Score

Get the complete analysis for ASX:CMB

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.42
Price